Cytokines and chemokines in the pathogenesis of murine Type 1 diabetes

Advances in Experimental Medicine and Biology

Volumn 520, Issue , 2003, Pages 133-158

  Meagher, C ^a   Sharif, S ^a   Hussain, S ^a   Cameron, Mark J ^a   Arreaza, Guillermo A ^a   Delovitch, Terry L ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 28; PROTEIN ANTIBODY; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

MURINAE;

EID: 0038748354     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0171-8_9     Document Type: Review

References (250)

1. Wong FS, Visintin I, Wen L et al. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J Exp Med 1996; 183:67-76.
2. Nagata M, Santamaria P, Kawamura T et al. Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J Immunol 1994; 152:2042-2050.
3. Wong FS, Dittel BN, Janeway CA. Transgenes and knockout mutations in animal models of type 1 diabetes and multiple sclerosis. Immunol Rev 1999; 169:93-104.
4. Wang B, Gonzalez A, Benoist C et al. The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol 1996; 26:1762-1769.
5. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NONThy-1a donors. Diabetes 1993; 42:44-55.
6. Haskins K, McDuffie M. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 1990; 249:1433-1436.
7. Rohane PW, Shimada A, Kim DT et al. Islet-infiltrating lymphocytes from prediabetic NOD mice rapidly transfer diabetes to NOD-scid/scid mice. Diabetes 1995; 44:550-554.
8. Kay TW, Parker JL, Stephens LA et al. RIP-beta 2-microglobulin transgene expression restores insulitis, but not diabetes, in beta 2-microglobulin null nonobese diabetic mice. J Immunol 1996; 157:3688-3693.
9. Bendelac A, Carnaud C, Boitard C et al. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 1987; 166:823-832.
10. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76:241-251.
11. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994; 12:635-673.
12. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 1994; 43:613-621.
13. De Carli M, D'Elios MM, Zancuoghi G et al. Human Th1 and Th2 cells: functional properties, regulation of development and role in autoimmunity. Autoimmunity 1994; 18:301-308.
14. von Herrath MG, Oldstone MB. Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med 1997; 185:531-539.
15. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:34-38.
16. Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD. Immunity 1997; 7:727-738.
17. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8:579-621.
18. Kuchroo VK, Martin CA, Greer JM et al. Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J Immunol 1993; 151:4371-4382.
19. Fox CJ, Danska JS. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. J Immunol 1997; 158:2414-2424.
20. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081-2095.
21. Rocken M, Urban J, Shevach EM. Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo. J Exp Med 1994; 179:1885-1893.
22. Hancock WW, Polanski M, Zhang J et al. Suppression of insulitis in nonobese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol 1995; 147:1193-1199.
23. Arreaza GA, Cameron MJ, Jaramillo A et al. Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. J Clin Invest 1997; 100:2243-2253.
24. Chen Y, Kuchroo VK, Inobe J et al. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994; 265:1237-1240.
25. Falcone M, Bloom BR. A T helper cell 2 (Th2) immune response against nonself antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J Exp Med 1997; 185:901-907.
26. Gallichan WS, Balasa B, Davies JD et al. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol 1999; 163:1696-1703.
27. Pakala SV, Kurrer MO, Katz JD. T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J Exp Med 1997; 186:299-306.
28. Mueller R, Bradley LM, Krahl T et al. Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity 1997; 7:411-418.
29. Lafaille JJ, Keere FV, Hsu AL et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997; 186:307-312.
30. Zipris D, Lazarus AH, Crow AR et al. Defective thymic T cell activation by concanavalin A and anti-CD3 in autoimmune nonobese diabetic mice. Evidence for thymic T cell anergy that correlates with the onset of insulitis. J Immunol 1991; 146:3763-3771.
31. Rapoport MJ, Jaramillo A, Zipris D et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178:87-99.
32. Berman MA, Sandborg CI, Wang Z et al. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol 1996; 157:4690-4696.
33. Wilson SB, Kent SC, Patton KT et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998; 391:177-181.
34. Cameron MJ, Arreaza GA, Zucker P et al. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 1997; 159:4686-4692.
35. Dosch H, Cheung RK, Karges W et al. Persistent T cell anergy in human type 1 diabetes. J Immunol 1999; 163:6933-6940.
36. Tominaga Y, Nagata M, Yasuda H et al. Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice. Clin Immunol Immunopathol 1998; 86:209-218.
37. Salomon B, Lenschow DJ, Rhee L et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-440.
38. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184:1093-1099.
39. Tian J, Atkinson MA, ClareSalzler M et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183:1561-1567.
40. Tian J, ClareSalzler M, Herschenfeld A et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996; 2:1348-1353.
41. Farilla L, Dotta F, Di Mario U et al. Presence of interleukin 4 or interleukin 10, but not both cytokines, in pancreatic tissue of two patients with recently diagnosed diabetes mellitus type I. Autoimmunity 2000; 32:161-166.
42. Judkowski V, Pinilla C, Schroder K et al. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J Immunol 2001; 166:908-917.
43. Asano M, Toda M, Sakaguchi N et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996; 184:387-396.
44. Tisch R, Wang B, Weaver DJ et al. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol 2001; 166:2122-2132.
45. Cameron MJ, Strathdee CA, Holmes KD et al. Biolistic-mediated interleukin 4 gene transfer prevents the onset of type 1 diabetes. Hum Gene Ther 2000; 11:1647-1656.
46. Homann D, Holz A, Bot A et al. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 1999; 11:463-472.
47. von Herrath MG, Dockter J, Oldstone MB. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1994; 1:231-242.
48. Oldstone MB, Nerenberg M, Southern P et al. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response. Cell 1991; 65:319-331.
49. Kaplan MH, Schindler U, Smiley ST et al. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4:313-319.
50. Hoglund P, Mintern J, Waltzinger C et al. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 1999; 189:331-339.
51. + T-cell responses. Nat Med 2001; 7:206-214.
52. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233-258.
53. Wang B, Gonzalez A, Hoglund P et al. Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 1998; 47:1207-1211.
54. Cameron MJ, Arreaza GA, Delovitch TL. Cytokine- and costimulation-mediated therapy of IDDM. Crit Rev Immunol 1997; 17:537-544.
55. Radu DL, Noben-Trauth N, Hu-Li J et al. A targeted mutation in the IL-4Ralpha gene protects mice against autoimmune diabetes. Proc Natl Acad Sci USA 2000; 97:12700-12704.
56. Sarukhan A, Lanoue A, Franzke A et al. Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model. EMBO J 1998; 17:71-80.
57. Zaccone P, Phillips J, Conget I et al. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes 1999; 48:1522-1528.
58. Novick D, Engelmann H, Wallach D et al. Soluble cytokine receptors are present in normal human urine. J Exp Med 1989; 170:1409-1414.
59. Ward LD, Howlett GJ, Discolo G et al. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp- 130. J Biol Chem 1994; 269:23286-23289.
60. Muraguchi A, Hirano T, Tang B et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167:332-344.
61. Lotz M, Jirik F, Kabouridis P et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 1988; 167:1253-1258.
62. Uyttenhove C, Coulie PG, Van Snick J. T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med 1988; 167:1417-1427.
63. Okada M, Kitahara M, Kishimoto S et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141:1543-1549.
64. Renauld JC, Vink A, Van Snick J. Accessory signals in murine cytolytic T cell responses. Dual requirement for IL-1 and IL-6. J Immunol 1989; 143:1894-1898.
65. Luger TA, Krutmann J, Kirnbauer R et al. IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol 1989; 143:1206-1209.
66. Campbell IL, Kay TW, Oxbrow L et al. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991; 87:739-742.
67. DiCosmo BF, Picarella D, Flavell RA. Local production of human IL-6 promotes insulitis but retards the onset of insulin-dependent diabetes mellitus in nonobese diabetic mice. Int Immunol 1994; 6:1829-1837.
68. Rincon M, Anguita J, Nakamura T et al. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997; 185:461-469.
69. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12:171-181.
70. Han HS, Jun HS, Utsugi T et al. Molecular role of TGF-beta, secreted from a new type of CD4+ suppressor T cell, NY4.2, in the prevention of autoimmune IDDM in NOD mice. J Autoimmun 1997; 10:299-307.
71. Strober W, Kelsall B, Fuss I et al. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 1997; 18:61-64.
72. Czarniecki CW, Chiu HH, Wong GH et al. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 1988; 140:4217-4223.
73. Kehrl JH, Taylor A, Kim SJ et al. Transforming growth factor-beta is a potent negative regulator of human lymphocytes. Ann N Y Acad Sci 1991; 628:345-353.
74. King C, Davies J, Mueller R et al. TGF-beta1 alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 1998; 8:601-613.
75. Sanvito F, Nichols A, Herrera PL et al. TGF-beta 1 overexpression in murine pancreas induces chronic pancreatitis and, together with TNF-alpha, triggers insulin-dependent diabetes. Biochem Biophys Res Commun 1995; 217:1279-1286.
76. Lee MS, Mueller R, Wicker LS et al. IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J Exp Med 1996; 183:2663-2668.
77. Moritani M, Yoshimoto K, Wong SF et al. Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF- beta1. J Clin Invest 1998; 102:499-506.
78. Piccirillo CA, Chang Y, Prud'homme GJ. TGF-beta1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J Immunol 1998; 161:3950-3956.
79. Suarez-Pinzon W, Korbutt GS, Power R et al. Testicular sertoli cells protect islet beta-cells from autoimmune destruction in NOD mice by a transforming growth factor-beta1-dependent mechanism. Diabetes 2000; 49:1810-1818.
80. Han HS, Jun HS, Utsugi T et al. A new type of CD4+ suppressor T cell completely prevents spontaneous autoimmune diabetes and recurrent diabetes in syngeneic islet-transplanted NOD mice. J Autoimmun 1996; 9:331-339.
81. Ziyadeh FN. Role of transforming growth factor beta in diabetic nephropathy. Exp Nephrol 1994; 2:137.
82. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000; 97:7667-7669.
83. Asseman C, Powrie F. Interleukin 10 is a growth factor for a population of regulatory T cells. Gut 1998; 42:157-158.
84. Stohlman SA, Pei L, Cua DJ et al. Activation of regulatory cells suppresses experimental allergic encephalomyelitis via secretion of IL-10. J Immunol 1999; 163:6338-6344.
85. Cua DJ, Groux H, Hinton DR et al. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J Exp Med 1999; 189:1005-1010.
86. Cua DJ, Hutchins B, LaFace DM et al. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol 2001; 166:602-608.
87. Sonoda KH, Faunce DE, Taniguchi M et al. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol 2001; 166:42-50.
88. Zhai Y, Kupiec-Weglinski JW. What is the role of regulatory T cells in transplantation tolerance? Curr Opin Immunol 1999; 11:497-503.
89. Cavani A, Mei D, Guerra E et al. Patients with allergic contact dermatitis to nickel and nonallergic individuals display different nickel-specific T cell responses. Evidence for the presence of effector CD8+ and regulatory CD4+ T cells. J Invest Dermatol 1998; 111:621-628.
90. Cavani A, Nasorri F, Prezzi C et al. Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol 2000; 114:295-302.
91. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71:169-175.
92. Nitta Y, Tashiro F, Tokui M et al. Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. Hum Gene Ther 1998; 9:1701-1707.
93. Moritani M, Yoshimoto K, Ii S et al. Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes. J Clin Invest 1996; 98:1851-1859.
94. Pauza ME, Neal H, Hagenbaugh A et al. T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes. Diabetes 1999; 48:1948-1953.
95. Maron R, Melican NS, Weiner HL. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. J Autoimmun 1999; 12:251-258.
96. Rabinovitch A, Suarez-Pinzon WL, Sorensen O et al. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice. Analysis of cytokine mRNA expression in the graft. Transplantation 1995; 60:368-374.
97. Faust A, Rothe H, Schade U et al. Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation 1996; 62:648-652.
98. Rapoport MJ, Mor A, Vardi P et al. Decreased secretion of Th2 cytokines precedes up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J Autoimmun 1998; 11:635-642.
99. Kallmann BA, Lampeter EF, Hanifi-Moghaddam P et al. Cytokine secretion patterns in twins discordant for Type I diabetes. Diabetologia 1999; 42:1080-1085.
100. Smith DK, Korbutt GS, Suarez-Pinzon WL et al. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice. Transplantation 1997; 64:1040-1049.
101. Lee MS, Wogensen L, Shizuru J et al. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 1994; 93:1332-1338.
102. Moritani M, Yoshimoto K, Tashiro F et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in nonobese diabetic mice. Int Immunol 1994; 6:1927-1936.
103. Balasa B, Davies JD, Lee J et al. IL-10 impacts autoimmune diabetes via a CD8+ T cell pathway circumventing the requirement for CD4+ T and B lymphocytes. J Immunol 1998; 161:4420-4427.
104. Balasa B, Van Gunst K, Jung N et al. Islet-specific expression of IL-10 promotes diabetes in nonobese diabetic mice independent of Fas, perforin, TNF receptor-1, and TNF receptor-2 molecules. J Immunol 2000; 165:2841-2849.
105. Balasa B, La Cava A, Van Gunst K et al. A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes. J Immunol 2000; 165:7330-7337.
106. Trepicchio WL, Wang L, Bozza M et al. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol 1997; 159:5661-5670.
107. Trepicchio WL, Bozza M, Pedneault G et al. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996; 157:3627-3634.
108. Hill GR, Cooke KR, Teshima T et al. Interleukin-11 promotes T cell polarization and prevents acute graft- versus-host disease after allogeneic bone marrow transplantation. J Clin Invest 1998; 102:115-123.
109. Nicoletti F, Zaccone P, Conget I et al. Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in NOD mice. Diabetes 1999; 48:2333-2339.
110. McKenzie AN. Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13. Pharmacol Ther 2000; 88:143-151.
111. McKenzie GJ, Emson CL, Bell SE et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998; 9:423-432.
112. McKenzie GJ, Bancroft A, Grencis RK et al. A distinct role for interleukin-13 in Th2-cell-mediated immune responses. Curr Biol 1998; 8:339-342.
113. Grunig G, Warnock M, Wakil AE et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282:2261-2263.
114. Li L, Xia Y, Nguyen A et al. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J Immunol 1999; 162:2477-2487.
115. McKenzie GJ, Fallon PG, Emson CL et al. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999; 189:1565-1572.
116. Lentsch AB, Shanley TP, Sarma V et al. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 1997; 100:2443-2448.
117. Cosentino G, Soprana E, Thienes CP et al. IL-13 down-regulates CD14 expression and TNF-alpha secretion in normal human monocytes. J Immunol 1995; 155:3145-3151.
118. Muchamuel T, Menon S, Pisacane P et al. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: Correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. J Immunol 1997; 158:2898-2903.
119. Morse MA, Lyerly HK, Li Y. The role of IL-13 in the generation of dendritic cells in vitro. J Immunother 1999; 22:506-513.
120. Cash E, Minty A, Ferrara P et al. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J Immunol 1994; 153:4258-4267.
121. Young DA, Lowe LD, Booth SS et al. IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J Immunol 2000; 164:3563-3572.
122. Kretowski A, Mysliwiec J, Kinalska I. In vitro inerleukin-13 production by peripheral blood in patients wirh newly diagnosed insulin-dependent diabetes mellitus and their first degree relatives. Scand J Immunol 2000; 51:321-325.
123. Mohrs M, Ledermann B, Kohler G et al. Differences between IL-4 and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 1999; 162:7302-7308.
124. LaFace DM, Peck AB. Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes. Diabetes 1989; 38:894-901.
125. Wicker LS, Miller BJ, Chai A et al. Expression of genetically determined diabetes and insuliris in the nonobese diabetic (NOD) mouse at the level of bone marrow-derived cells. Transfer of diabetes and insulitis to nondiabetic (NOD X B10) F1 mice with bone marrow cells from NOD mice. J Exp Med 1988; 167:1801-1810.
126. Ikehara S, Kawamura M, Takao F et al. Organ-specific and systemic autoimmune diseases originare from defecrs in hematopoietic stem cells. Proc Natl Acad Sci USA 1990; 87:8341-8344.
127. Yasumizu R, Sugiura K, Iwai H et al. Treatment of type 1 diabetes mellitus in nonobese diabetic mice by transplantation of allogeneic bone marrow and pancreatic tissue. Proc Narl Acad Sci USA 1987; 84:6555-6557.
128. Langmuir PB, Bridgett MM, Bothwell AL et al. Bone marrow abnormalities in the nonobese diabetic mouse. Int Immunol 1993; 5:169-177.
129. Serreze DV, Gaedeke JW, Leiter EH. Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci USA 1993; 90:9625-9629.
130. Morel PA, Vasquez AC, Feili-Hariri M. Immunobiology of DC in NOD mice. J Leukoc Biol 1999; 66:276-280.
131. Lee M, Kim AY, Kang Y. Defects in the differentiation and function of bone marrow-derived dendriric cells in nonobese diabetic mice. J Korean Med Sci 2000; 15:217-223.
132. Jeong MC, Izikson L, Uccelli A, Brocke S, Oksenberg JR. Differential display analysis of murine encephalitogenic mRNA. Int Immunol 1998; 10:1819-1823.
133. Offner H, Vainiene M, Celnik B et al. Coculture of TCR peptide-specific T cells with basic protein-specific T cells inhibits proliferation, IL-3 mRNA, and transfer of experimental autoimmune encephalomyelitis. J Immunol 1994; 153:4988-4996.
134. Ito A, Aoyanagi N, Maki T. Regulation of autoimmune diabetes by interleukin 3-dependent bone marrow-derived cells in NOD mice. J Autoimmun 1997; 10:331-338.
135. Burlinson EL, Drakes ML, Wood PJ. Differential patterns of production of granulocyte macrophage colony stimulating factor, IL-2, IL-3 and IL-4 by cultured islets of Langerhans from nonobese diabetic and nondiabetic strains of mice. Int Immunol 1995; 7:79-87.
136. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147.
137. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39:1005-1029.
138. Lacy PE, Finke EH. Activation of intraislet lymphoid cells causes destruction of islet cells. Am J Pathol 1991; 138:1183-1190.
139. Lacy PE. The intraislet macrophage and type I diabetes. Mt Sinai J Med 1994; 61:170-174.
140. Heitmeier MR, Scarim AL, Corbett JA. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1. J Biol Chem 1997; 272:13697-13704.
141. Corbett JA, McDaniel ML. Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase. J Exp Med 1995; 181:559-568.
142. Arnush M, Scarim AL, Heitmeier MR et al. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J Immunol 1998; 160:2684-2691.
143. Arnush M, Heitmeier MR, Scarim AL et al. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998; 102:516-526.
144. McDaniel ML, Kwon G, Hill JR et al. Cytokines and nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med 1996; 211:24-32.
145. Corbett JA, Wang JL, Sweetland MA et al. Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J Clin Invest 1992; 90:2384-2391.
146. Yamada K, Takane-Gyotoku N, Yuan X et al. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996; 39:1306-1312.
147. Amrani A, Verdaguer J, Thiessen S et al. IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes. J Clin Invest 2000; 105:459-468.
148. Hohmeier HE, Thigpen A, Tran VV et al. Stable expression of manganese superoxide dismutase (MnSOD) in insulinoma cells prevents IL-1beta- induced cytotoxicity and reduces nitric oxide production. J Clin Invest 1998; 101:1811-1820.
149. Stassi G, De Maria R, Trucco G et al. Nitric oxide primes pancreatic bera cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997; 186:1193-1200.
150. Giannoukakis N, Rudert WA, Ghivizzani SC et al. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999; 48:1730-1736.
151. Wogensen L, Helqvist S, Pociot F et al. Intra-peritoneal administration of interleukin-1 beta induces impaired insulin release from the perfused rat pancreas. Autoimmunity 1990; 7:1-12.
152. Wang Y, Goodman M, Lumerman J et al. In vivo administration of interleukin-1 inhibits glucose-stimulated insulin release. Diabetes Res Clin Pract 1989; 7:205-211.
153. Wilson CA, Jacobs C, Baker P et al. IL-1 beta modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat. J Immunol 1990; 144:3784-3788.
154. Jacob CO, Also S, Michie SA et al. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): Similarities between TNF-alpha and interleukin-1. Proc Natl Acad Sci USA 1990; 87:968-972.
155. Nicoletti F, Di Marco R, Barcellini W et al. Protection from experimental autoimmune diabetes in the nonobese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol 1994; 24:1843-1847.
156. Cailleau C, Diu-Hercend A, Ruuth E et al. Treatment with neutralizing antibodies specific for IL-1beta prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 1997; 46:937-940.
157. Refaeli Y, Van Parijs L, London CA et al. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998; 8:615-623.
158. Kroemer G, Wick G. The role of interleukin 2 in autoimmunity. Immunol Today 1989; 10:246-251.
159. Schorle H, Holtschke T, Hunig T et al. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991; 352:621-624.
160. Smith KA. Interleukin-2. Curr Opin Immunol 1992; 4:271-276.
161. Miyajima A, Kitamura T, Harada N et al. Cytokine receptors and signal transduction. Annu Rev Immunol 1992; 10:295-331.
162. Strom TB, Kelley VR, Murphy JR et al. Interleukin-2 receptor-directed therapies: Antibody-or cytokine-based targeting molecules. Annu Rev Med 1993; 44:343-353.
163. Waldmann TA. The IL-2/IL-2 receptor system: A target for rational immune intervention. Immunol Today 1993; 14:264-270.
164. Zheng XX, Steele AW, Hancock WW et al. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J Immunol 1999; 163:4041-4048.
165. Kelley VE, Gaulton GN, Hattori M et al. Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 1988; 140:59-61.
166. Allison J, Malcolm L, Chosich N et al. Inflammation but not autoimmunity occurs in transgenic mice expressing constitutive levels of interleukin-2 in islet beta cells. Eur J Immunol 1992; 22:1115-1121.
167. Allison J, Oxbrow L, Miller JF. Consequences of in situ production of IL-2 for islet cell death. Int Immunol 1994; 6:541-549.
168. Allison J, McClive P, Oxbrow L et al. Genetic requirements for acceleration of diabetes in nonobese diabetic mice expressing interleukin-2 in islet beta-cells. Eur J Immunol 1994; 24:2535-2541.
169. von Herrath MG, Allison J, Miller JF et al. Focal expression of interleukin-2 does not break unresponsiveness to "self" (vital) antigen expressed in beta cells but enhances development of autoimmune disease (diabetes) after initiation of an anti-self immune response. J Clin Invest 1995; 95:477-485.
170. Lyons PA, Armitage N, Argentina F et al. Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: Identification of a candidate segment of ancestral DNA by haplotype mapping. Genome Res 2000; 10:446-453.
171. Denny P, Lord CJ, Hill NJ et al. Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes 1997; 46:695-700.
172. Podolin PL. Wilusz MB, Cubbon RM et al. Differential glycosylation of interleukin-2, the molecular basis for the NOD Idd3 type 1 diabetes gene? Cytokine 2000; 12:477-482.
173. Caspi RR. IL-12 in autoimmunity. Clin Immunol Immunopathol 1998; 88:4-13.
174. Adorini L. Interleukin 12 and autoimmune diabetes. Nat Genet 2001; 27:131-132.
175. Trembleau S, Germann T, Gately MK et al. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995; 16:383-386.
176. Rabinovitch A, Suarez-Pinzon WL, Sorensen O. Interleukin 12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. J Autoimmun 1996; 9:645-651.
177. Rothe H, Burkart V, Faust A et al. Interleukin-12 gene expression mediates the accelerating effect of cyclophosphamide in autoimmune disease. Ann NY Acad Sci 1996; 9:645-651.
178. O'Hara RM, Henderson SL, Nagelin A. Prevention of a Th1 disease by a Th1 cytokine: IL-12 and diabetes in NOD mice. Ann NY Acad Sci 1996; 795:241-249.
179. Nicoletti F, DiMarco R, Zaccone P et al. Endogenous interleukin-12 only plays a key pathogenetic role in nonobese diabetic mouse diabetes during the very early stages of the disease. Immunology 1999; 97:367-370.
180. Fujihira K, Nagata M, Moriyama H et al. Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice. Diabetes 2000; 49:1998-2006.
181. Rothe H, O'Hara RM, Martin S et al. Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)-12 antagonist IL-12(p40)2. Diabetologia 1997; 40:641-646.
182. Trembleau S, Penna G, Gregori S et al. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 1997; 27:2330-2339.
183. Gracie JA, Forsey RJ, Chan WL et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104:641-646.
184. Yasuda H, Nagata M, Arisawa K et al. Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. J Clin Invest 1998; 102:1807-1814.
185. Trembleau S, Penna G, Gregori S et al. Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice. J Immunol 1999; 163:2960-2968.
186. Rabinovitch A, Suarez-Pinzon WL, Sorensen O et al. IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J Immunol 1995; 154:4874-4882.
187. Debray-Sachs M, Carnaud C, Boitard C et al. Prevention of diabetes in NOD mice treated with antibody to routine IFN gamma. J Autoimmun 1991; 4:237-248.
188. Kay TW, Campbell IL, Oxbrow L et al. Overexpression of class I major histocompatibility complex accompanies insulitis in the nonobese diabetic mouse and is prevented by anti-interferon-gamma antibody. Diabetologia 1991; 34:779-785.
189. Campbell IL, Iscaro A, Harrison LC. IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans. J Immunol 1988; 141:2325-2329.
190. Dunger A, Cunningham JM, Delaney CA et al. Tumor necrosis factor-alpha and interferon-gamma inhibit insulin secretion and cause DNA damage in unweaned-rat islets. Extent of nitric oxide involvement. Diabetes 1996; 45:183-189.
191. Thomas HE, Parker JL, Schreiber RD et al. IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J Clin Invest 1998; 102:1249-1257.
192. Sarvetnick N, Liggitt D, Pitts SL et al. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell 1988; 52:773-782.
193. Nicoletti F, Zaccone P, Di Marco R et al. Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with antirat interferon-gamma antibody. Endocrinology 1997; 138:281-288.
194. Nicoletti F, Zaccone P, Di Marco R et al. The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology 1996; 137:5567-5575.
195. Wang B, Andre I, Gonzalez A et al. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94:13844-13849.
196. Kanagawa O, Xu G, Tevaarwerk A et al. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. J Immunol 2000; 164:3919-3923.
197. Serreze DV, Post CM, Chapman HD et al. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 2000; 49:2007-2011.
198. Hultgren B, Huang X, Dybdal N et al. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996; 45:812-817.
199. Serreze DV, Chapman HD, Post CM et al. Th1 to Th2 cytokine shifts in nonobese diabetic mice: Sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J Immunol 2001; 166:1352-1359.
200. Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378:88-91.
201. Dayer JM. Interleukin-18, rheumatoid arthritis, and tissue destruction. J Clin Invest 1999; 104:1337-1339.
202. Rothe H, Jenkins NA, Copeland NG et al. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. J Clin Invest 1997; 99:469-474.
203. Rothe H, Hibino T, Itoh Y et al. Systemic production of interferon-gamma inducing factor (IGIF) versus local IFN-gamma expression involved in the development of Th1 insulitis in NOD mice. J Autoimmun 1997; 10:251-256.
204. Andre-Schmutz I, Hindelang C, Benoist C et al. Cellular and molecular changes accompanying the progression from insulitis to diabetes. Eur J Immunol 1999; 29:245-255.
205. Krook H, Wallstrom J, Sandler S. Function of rat pancreatic islets exposed to interleukin-18 in vitro. Autoimmunity 1999; 29:263-267.
206. Hong TP, Andersen NA, Nielsen K et al. Interleukin-18 mRNA, but not interleukin-18 receptor mRNA, is constitutively expressed in islet beta-cells and up-regulated by interferon-gamma. Eur Cytokine Netw 2000; 11:193-205.
207. Rothe H, Hausmann A, Casteels K et al. IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis. J Immunol 1999; 163:1230-1236.
208. Xu D, Trajkovic V, Hunter D et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol 2000; 30:3147-3156.
209. Leite-De-Moraes MC, Hameg A, Pacilio M et al. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: A pro-Th2 effect of IL-18 exerted through NKT cells. J Immunol 2001; 166:945-951.
210. Green EA, Flavell RA. Tumor necrosis factor-alpha and the progression of diabetes in nonobese diabetic mice. Immunol Rev 1999; 169:11-22.
211. Green EA, Eynon EE, Flavell RA. Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 1998; 9:733-743.
212. Campbell IL, Cutri A, Wilkinson D et al. Intercellular adhesion molecule 1 is induced on isolated endocrine islet cells by cytokines but not by reovirus infection. Proc Natl Acad Sci USA 1989; 86:4282-4286.
213. Yagi N, Yokono K, Amano K et al. Expression of intercellular adhesion molecule 1 on pancreatic beta- cells accelerates beta-cell destruction by cytotoxic T-cells in murine autoimmune diabetes. Diabetes 1995; 44:744-752.
214. Stephens LA, Thomas HE, Ming L et al. Tumor necrosis factor-alpha-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic beta cells. Endocrinology 1999; 140:3219-3227.
215. Pujol-Borrell R, Todd I, Doshi M et al. HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 1987; 326:304-306.
216. Campbell IL, Oxbrow L, West J et al. Regulation of MHC protein expression in pancreatic beta-cells by interferon-gamma and tumor necrosis factor-alpha. Mol Endocrinol 1988; 2:101-107.
217. Held W, MacDonald HR, Weissman IL et al. Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci USA 1990; 87:2239-2243.
218. Yang XD, Tisch R, Singer SM et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994; 180:995-1004.
219. Jacob CO, Aiso S, Schreiber RD et al. Monoclonal anti-tumor necrosis factor antibody renders nonobese diabetic mice hypersensitive to irradiation and enhances insulitis development. Int Immunol 1992; 4:611-614.
220. Picarella DE, Kratz A, Li CB et al. Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets leads to insulitis, not diabetes. Distinct patterns of inflammation in TNF-alpha and TNF-beta transgenic mice. J Immunol 1993; 150:4136-4150.
221. Higuchi Y, Herrera P, Muniesa P et al. Expression of a tumor necrosis factor alpha transgene in murine pancreatic beta cells results in severe and permanent insulitis without evolution towards diabetes. J Exp Med 1992; 176:1719-1731.
222. Grewal IS, Grewal KD, Wong FS et al. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996; 184:1963-1974.
223. Cope AP, Liblau RS, Yang XD et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997; 185:1573-1584.
224. Cope A, Ettinger R, McDevitt H. The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997; 148:307-312.
225. Rothe H, Kolb H. The APC1 concept of type I diabetes. Autoimmunity 1998.
226. Green EA, Wong FS, Eshima K et al. Neonatal tumor necrosis factor alpha promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8(+) T cells. J Exp Med 2000; 191:225-238.
227. Balasa B, Krahl T, Patstone G et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159:4620-4627.
228. Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 1996; 7:93-124.
229. Kagi D, Ho A, Odermatt B et al. TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes. J Immunol 1999; 162:4598-4605.
230. Pakala SV, Chivetta M, Kelly CB et al. In autoimmune diabetes the transition from benigh to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. J Exp Med 1999; 189:1053-1062.
231. Green EA, Flavell RA. The temporal importance of TNFalpha expression in the development of diabetes. Immunity 2000; 12:459-469.
232. Guerder S, Meyerhoff J, Flavell R. The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1994; 1:155-166.
233. Herrera PL, Harlan DM, Vassalli P. A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways: Possible role of membrane TNF. Proc Natl Acad Sci USA 2000; 97:279-284.
234. Herrera PL, Harlan DM, Fossati L et al. A CD8+ T-lymphocyte-mediated and CD4+ T-lymphocyte-independent autoimmune diabetes of early onset in transgenic mice. Diabetologia 1994; 37:1277-1279.
235. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000; 12:121-127.
236. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: More than an attraction. Immunity 1998; 9:1-11.
237. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000; 18:593-620.
238. Gill BM, Jaramillo A, Ma L et al. Genetic linkage of thymic T-cell proliferative unresponsiveness to mouse chromosome 11 in NOD mice. A possible role for chemokine genes. Diabetes 1995; 44:614-619.
239. Butterfield RJ, Sudweeks JD, Blankenhorn EP et al. New genetic loci that control susceptibility and symptoms of experimental allergic encephalomyelitis in inbred mice. J Immunol 1998; 161:1860-1867.
240. Teuscher C, Butterfield RJ, Ma RZ et al. Sequence polymorphisms in the chemokines Scya1 (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7, a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis. J Immunol 1999; 163:2262-2266.
241. Standiford TJ, Kunkel SL, Liebler JM et al. Gene expression of macrophage inflammatory protein-1 alpha from human blood monocytes and alveolar macrophages is inhibited by interleukin-4. Am J Respir Cell Mol Biol 1993; 9:192-198.
242. Herold KC, Lu J, Rulifson I et al. Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. J Immunol 1997; 159:4150-4153.
243. Cameron MJ, Arreaza GA, Grattan M et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol 2000; 165:1102-1110.
244. Grewal IS, Rutledge BJ, Fiorillo JA et al. Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: Abrogation by a second transgene expressing systemic MCP-1. J Immunol 1997; 159:401-408.
245. Karpus WJ, Lukacs NW, McRae BL et al. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995; 155:5003-5010.
246. Karpus WJ, Kennedy KJ. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997; 62:681-687.
247. Kunkel SL. Th1- and Th2-type cytokines regulate chemokine expression. Biol Signals 1996; 5:197-202.
248. Loetscher P, Uguccioni M, Bordoli L et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998; 391:344-345.
249. Bonecchi R, Bianchi G, Bordignon PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187:129-134.
250. Bradley LM, Asensio VC, Schioetz LK et al. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 1999; 162:2511-2520.